Ann Intern Med

1. GOLDMAN JM, Mitchell KM, Hopkins RH Jr
   ACP Supports Updated Adult Vaccination Schedules From AAFP and ACOG.
   Ann Intern Med. 2026 Aug 4. doi: 10.7326/ANNALS-26-03113.
   

   >> Share

   
   
2. CHEN V, Glatt AE
   In older adults, mRNA-1010 vs. a licensed standard-dose influenza vaccine reduced influenza A- or B-related ILI at a median 181 d.
   Ann Intern Med. 2026 Aug 4. doi: 10.7326/ANNALS-26-02527.
   

   >> Share

   
   

   
   BMJ

3. WISE J
   "Fridge-free" vaccine for tetanus-diphtheria shows promise in first human trial.
   BMJ. 2026;394:e100517.
   

   >> Share

   
   
4. LANG K
   Ebola: how soon could a Bundibugyo vaccine be ready?
   BMJ. 2026;394:e100450.
   

   >> Share

   
   

   
   Clin Infect Dis

5. MUNBLIT D, Buonsenso D, Olliaro PL, Semple MG, et al
   Vaccines, Bias, and the Perils of Non-peer-reviewed Studies: Fueling Misinformation and Vaccine Hesitancy.
   Clin Infect Dis. 2026 Aug 5:ciag403. doi: 10.1093.
   

   >> Share

   
   
6. PARDO-SECO J, Rodriguez-Tenreiro-Sanchez C, Gine-Vazquez I, Mallah N, et al
   A Bayesian Re-Analysis of the GALFLU Trial of high dose versus standard dose influenza vaccine against hospitalisation outcomes.
   Clin Infect Dis. 2026 Aug 3:ciag466. doi: 10.1093.
   

   >> Share

   
   

   
   Infect Immun

7. HOWLADER DR, Das S, Biswas S, Dietz ZK, et al
   A multivalent subunit vaccine augments pre-existing immunity to protect against T3SS-positive Pseudomonas aeruginosa but reveals immunological interference against ExlA-positive strains.
   Infect Immun. 2026 Aug 4:e0017526. doi: 10.1128/iai.00175.
   

   >> Share

   
   

   
   J Infect

8. LI X, Mercade-Besora N, Lam AS, Barboza C, et al
   Effectiveness and waning of the fourth dose mRNA COVID-19 vaccines for the prevention of SARS-CoV2 infection related hospitalisations and deaths.
   J Infect. 2026 Aug 5:106825. doi: 10.1016/j.jinf.2026.106825.
   

   >> Share

   
   
9. ZHANG Y, Shrestha S, Feaheny F, Pant D, et al
   Impact of dosing interval on immunogenicity following a heterologous typhoid conjugate vaccine booster in Nepalese children: an observational study.
   J Infect. 2026 Aug 5:106823. doi: 10.1016/j.jinf.2026.106823.
   

   >> Share

   
   

   
   J Infect Dis

10. LIMA VD, Hussain SS, Yan J, Copp E, et al
    Incidence of Herpes Zoster Infection (Shingles) Among Adults Living With and Without HIV in British Columbia, Canada: A Population-Based Study.
    J Infect Dis. 2026 Mar 10:jiag118. doi: 10.1093.
    

    >> Share

    
    

    
    J Pediatr

11. GROOM HC, Brooks N, Dandamudi P, Smith N, et al
    Meningococcal B Vaccination Patterns Across 10 Integrated Health Systems within Vaccine Safety Datalink, 2015-2023.
    J Pediatr. 2026 Aug 4:115274. doi: 10.1016/j.jpeds.2026.115274.
    

    >> Share

    
    

    
    PLoS Comput Biol

12. BRETT TS, Tredennick A, Briga M, Coudeville L, et al
    Quantifying the impact of vaccination on pertussis dynamics in Sweden.
    PLoS Comput Biol. 2026;22:e1014538.
    

    >> Share

    
    

    
    PLoS One

13. ORDAK M
    Statistical misreasoning in online content about vaccines: Implications and recommendations for addressing disinformation.
    PLoS One. 2026;21:e0355341.
    

    >> Share

    
    
14. THARAKHET K, Prompetchara E, Khawsang C, Saithong S, et al
    Cross-serotype immunity elicited by a consensus dengue NS1 mRNA vaccine in mice.
    PLoS One. 2026;21:e0355389.
    

    >> Share

    
    

    
    Science

15. AGUIAR M
    Dengue vaccines need long-term surveillance.
    Science. 2026;393:572.
    

    >> Share

    
    
16. COHEN J
    Weekly HIV pill moves closer but vaccine studies face new questions.
    Science. 2026;393:549-550.
    

    >> Share

    
    

    
    Vaccine

17. HAPOSAN JH, Thobari JA, Watts E, Pitzer VE, et al
    Cost-effectiveness and budget impact analyses of introducing typhoid conjugate vaccine into Indonesia's national immunisation program.
    Vaccine. 2026;90:129008.
    

    >> Share

    
    
18. NKODILA AN, Luvande RO, Nsana AB, Wembonyama SO, et al
    Systemic barriers to achieving yellow fever vaccination coverage targets among children aged 9-23 months in the Democratic Republic of the Congo.
    Vaccine. 2026;88:128995.
    

    >> Share

    
    
19. FREITAS CS, Lage DP, Pimenta BL, Falcao KOM, et al
    Recombinant vaccine plus anti-parasitic agent in an immunotherapeutic schedules induce partial regression of tegumentary leishmaniasis in a murine model.
    Vaccine. 2026;89:128990.
    

    >> Share

    
    
20. XU N, Wang L, Zhao C, Shen Y, et al
    Advances in clinical immunogenicity evaluation of influenza vaccines.
    Vaccine. 2026;89:128989.
    

    >> Share

    
    
21. SANDERS JG, Kroese F, Mehra S, Stok M, et al
    Switching the default: a formative evaluation of pre-booked appointments on COVID-19 vaccination uptake and effects on intended uptake.
    Vaccine. 2026;89:128967.
    

    >> Share

    
    
22. RUSSELL FA, Fisher MA, Leahy D, Harris J, et al
    Stability of Chlamydia pecorum MOMP at 37 degrees C: suitability for use in delayed-release vaccine implants in koalas (Phascolarctos cinereus).
    Vaccine. 2026;89:128991.
    

    >> Share

    
    
23. ZUNDONG Y, Xiaoxue L, Rodewald L, Fuzhen W, et al
    Entering into life-course immunization: Process, significance, and prospects of HPV vaccine inclusion into the national immunization program of China.
    Vaccine. 2026;89:129000.
    

    >> Share

    
    
24. AUGUSTO LV, de Araujo LP, Silva EN, Gutierres JM, et al
    Intersection of vaccination, health literacy, education, and communication in South America: A scientometric mapping.
    Vaccine. 2026;89:128986.
    

    >> Share

    
    
25. DJAWE K, Aigbogun E, Zoumanigui JS, Berete A, et al
    Strategies and lessons learned from a type 1 circulating vaccine-derived poliovirus (cVDPV) outbreak affecting adult population: Madagascar, 2020-2023.
    Vaccine. 2026;89:128987.
    

    >> Share

    
    
26. NEPALI R, King C, Leask J, Campbell E, et al
    A systematic review of knowledge, attitudes, and behaviour towards Japanese encephalitis vaccination.
    Vaccine. 2026;89:128999.
    

    >> Share

    
    
27. MAZIBUKO L, Hoor D, Nxumalo V, Nxumalo S, et al
    The association of individual, interpersonal and social support factors with willingness to vaccinate against COVID-19 in rural South Africa.
    Vaccine. 2026;89:128998.
    

    >> Share

    
    
28. DE WALS P
    The marketing authorization of vaccines is not an exact science: the 20-valent pneumococcal conjugate vaccine (PCV-20) is an example.
    Vaccine. 2026;90:128984.
    

    >> Share

    
    
29. DOUCETTE EJ, Ricketson LJ, Murguia-Favela L, Wright N, et al
    Clinical features and outcomes of pediatric breakthrough invasive pneumococcal disease (IPD) in vaccinated children in Calgary, Alberta, Canada, 2003-2024.
    Vaccine. 2026;90:128977.
    

    >> Share

    
    
30. WEI W, Yang R, Wang Z, Feng S, et al
    A novel inactivated vaccine for cross-protection against Actinobacillus pleuropneumoniae in pigs.
    Vaccine. 2026;90:129010.
    

    >> Share

    
    
31. DAVIES HG, Rukundo G, Komugisha C, Kipyeko S, et al
    Baseline adverse birth outcomes in a prospective pregnancy cohort in Uganda: Evidence to inform maternal vaccine readiness.
    Vaccine. 2026;90:128952.
    

    >> Share

    
    

    
    Virology

32. SABIR AJ, Ross TM
    Advancing human metapneumovirus vaccine development through fusion protein stabilization.
    Virology. 2026;624:111043.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share